Inhibitors | Comment | Organism | Structure |
---|---|---|---|
3-[(2S)-2-[[(2',4'-dimethoxybiphenyl-3-yl)sulfonyl]amino]-3-(4-[2-(methylcarbamoyl)aminoethyl]piperidin-1-yl)-3-oxopropyl]benzenecarboximidamide | - |
Sus scrofa | |
3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(2',4'-dichlorobiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl]benzenecarboximidamide | - |
Sus scrofa | |
4-(2-aminoethyl)-benzosulphonylfluoride | nonselective inhibitor | Sus scrofa |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Sus scrofa | F1S6D6 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
IPEC-J2 cell | intestinal IPEC-J2 cell monolayer | Sus scrofa | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
butyloxycarbonyl-Gln-Ala-Arg-7-amido-4-methylcoumarin + H2O | - |
Sus scrofa | ? | - |
? |
General Information | Comment | Organism |
---|---|---|
physiological function | suppression of matriptase activity by inhibitors 3-[(2S)-2-[[(2',4'-dimethoxybiphenyl-3-yl)sulfonyl]amino]-3-(4-[2-(methylcarbamoyl)aminoethyl]piperidin-1-yl)-3-oxopropyl]benzenecarboximidamide and 3-[(2S)-3-[4-(2-aminoethyl)piperidin-1-yl]-2-[[(2',4'-dichlorobiphenyl-3-yl)sulfonyl]amino]-3-oxopropyl]benzenecarboximidamide leads to decreased transepithelial electrical resistance of the cell monolayer and to an enhanced transport of fluorescently labelled dextran | Sus scrofa |